*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
No Data found.
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Cannabinoid receptors: A potential target for osteoporosis pain

Author: , PALLABI PANJA, NAUREEN AFROSE, MR. SUKARNA BASU, DR. MUKESH KUMAR DAS, DR. SANDIPAN DASGUPTA
Abstract: Osteoporosis, a systemic bone metabolic disorder which is characterized by explicit decline in bone density. Besides, microstructural alterations of the bone are very common in old people with osteoporosis. In menopausal women, prevalent management strategies for osteoporosis involve opioid analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) which relieve the pain temporarily but they have several side effects like tolerance, addiction, safety, etc. Recent advancement in studies indicates cannabinoid receptors are the new target in osteoporosis pain. Cannabinoid receptors (type 1 and type 2) play a remarkable role in the stimulation of bone formation and in the inhibition of bone resorption. The deficiency of this anti-resorptive agent accelerates age-dependent bone loss due to marked elevation in bone resorption and reduced bone formation. GRP55 and transient receptor potential vanilloid type 1 (TRPV1) are two other receptors that are co-expressed in bone cells, which show involvement in bone homeostasis. Recent studies suggest that GPR55 cannabidiol antagonist increases the activity of osteoblast and decreases the function of osteoclast. The opposing effects of TRPV1 vs. Cannabinoid receptor (CBR1 and CBR2) in regulating human osteoblast activity is also a significant aspect of this concern. Both TRPV1 and GRP55 exert opposite action when compared to CBR1 and CBR2. So multi-targeting is more convenient rather than single targeting. The involvement of a nervous system in osteoporosis, especially in the pain signalling mechanism of glial cells is also an important feature to be further studied. This review is all about targeting the cannabinoid receptors in the treatment of osteoporosis pain and its recent development.
Keyword: Cannabinoid receptor, TRPV1, Osteoporosis, CBR1, CBR2
DOI: https://doi.org/10.31838/ijpr/2021.13.03.149
Download: Request For Article
 
Clients

Clients

Clients

Clients

Clients
ONLINE SUBMISSION
USER LOGIN
Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free